Compare Illumina, Inc. (ILMN) vs ING Groep NV (ING) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs ING Groep NV — how do they compare? Illumina, Inc. trades at $278.17 (market cap $39.95B), while ING Groep NV trades at $33.37 (market cap $93.76B). The key difference: ING Groep NV is far larger — about 2.3× Illumina, Inc.'s market cap, and ING Groep NV pays a 3.95% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and ING Groep NV for 94 Days on average.
| ILMN | ING | |
|---|---|---|
Market Cap | $39.95B | $93.76B |
Volume | 3,169,503 | 4,620,220 |
Sector | Health | Financials |
52-Week High | $293.69 | $37.27 |
52-Week Low | $91.00 | $23.66 |
Typical Hold Time | 83 Days | 94 Days |
Enterprise Value | $41.31B | $236.48B |
Dividend Yield | — | 3.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ILMN trades at $264.40, down 1.25% on the day, but remains near its recent 52-week high of $278.99 (Defense World, 2026-10-01). The stock has surged 94.9% year-to-date (Zacks Investment Research, 2026-09-24), supported by strong earnings beats in recent quarters and a bullish technical trend. Fundamentals show a significant turnaround, with 2025 net income reaching $850 million after prior losses, though valuation ratios like a P/E of 49.36 are elevated. The pending inclusion in the S&P 500 (PRNewsWire, 2026-09-04) adds a positive catalyst.
The outlook is positive, driven by sequencing growth, AI integration in genomics, and improved profitability. However, risks include high valuation sensitivity, cost volatility, and competitive pressures in the life sciences sector. Analyst consensus is bullish with a 54% buy rating, but the average price target of $241 suggests limited near-term upside from current levels.
ING trades at $33.43, down 1.44% today, with technical indicators showing bearish momentum despite recent earnings beats. The company reported strong Q2 2026 results with revenue growth and raised 2027 ROE targets above 16%. Valuation metrics show a P/E of 12.86 and P/B of 1.68, while analyst consensus remains strongly positive with 64.7% buy ratings.
ING presents a compelling investment case with solid profitability (28.3% net margin) and consistent earnings outperformance, though negative cash flow trends and regulatory challenges in Australia warrant caution. The stock's current technical weakness may offer entry opportunities for long-term investors attracted by the company's growth trajectory and dividend yield.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →
